Prophylactic antiemetics therapy against gynecologic cancer chemotherapy.

Lee, Keun Ho; Kwon, Yong Il

doi:2011.54.3.127

Obstet Gynecol Sci > Volume 54(3); 2011 > Article

Review

Korean Journal of Obstetrics & Gynecology 2011;54(3):127-131.
DOI: https://doi.org/10.5468/KJOG.2011.54.3.127 Published online March 1, 2011.

Prophylactic antiemetics therapy against gynecologic cancer chemotherapy.

Keun Ho Lee, Yong Il Kwon

¹Department of Obstetrics & Gynecology, The Catholic University of Korea School of Medicine, Seoul, Korea.
²Department of Obstetrics & Gynecology, Hallym University School of Medicine, Seoul, Korea. kbgy@hallym.or.kr

Abstract

Nausea and vomiting associated with gynecologic cancer chemotherapy are experienced by most of patients receiving chemotherapy. Assessment of vomiting risk by chemotherapy and risk factor are mandatory for rescue of chemotherapy induced nausea and vomiting (CINV). Piled-up evidence based medicine result in prophylactic antiemetics guideline from American Society of Clinical Oncology, Multinational Association for Supportive Care in Cancer, and National Comprehensive Cancer Network. Combination of serotonin receptor antagonist, dexamethason, and with/without NK1 antagonist is the best prophylaxis in patients receiving highly and moderate emetogenic chemotherapy. Other new regimens (palonosetron, transdermal granisetron) are introduced to relieve the active symptom of delayed CINV. Comprehensive understading of pathophysiology of CINV and tailored therapy for the patients are vital in prophylactic antiemetics therapy against gynecologic cancer chemotherapy.

Key Words: Nausea, Vomiting, Antiemetics, Guideline